Skip to main content

Diastolic dysfunction on echocardiography

Diastology

Diastolic dysfunction on echocardiography: a comprehensive, guideline-oriented review

Diastolic dysfunction refers to impaired left ventricular (LV) filling due to abnormal relaxation, increased chamber stiffness, or both, leading to elevated LV filling pressures. It is a central mechanism in heart failure with preserved ejection fraction (HFpEF) and contributes significantly to symptoms, prognosis, and management decisions.


PHYSIOLOGY OF DIASTOLE

LV diastole has four phases:


1. Isovolumic relaxation (IVRT): energy-dependent myocardial relaxation after aortic valve closure



2. Early rapid filling: pressure gradient–driven filling (E wave)



3. Diastasis: minimal flow when LA and LV pressures equalize



4. Atrial contraction: late filling (A wave)




Diastolic dysfunction develops when relaxation is delayed, compliance is reduced, or left atrial (LA) pressure rises to compensate.


ECHOCARDIOGRAPHIC PARAMETERS FOR DIASTOLIC ASSESSMENT


1. Mitral inflow Doppler

Measured in apical 4-chamber view with pulsed-wave Doppler at mitral leaflet tips.




Key variables: • E wave: early diastolic filling velocity

• A wave: atrial contraction velocity

• E/A ratio

• Deceleration time (DT) of E wave

• Isovolumic relaxation time (IVRT)


Patterns: • Impaired relaxation: E/A < 1, prolonged DT, prolonged IVRT

• Pseudonormal: E/A appears normal due to raised LA pressure

• Restrictive filling: E/A ≥ 2, short DT, short IVRT


Limitations: • Highly preload dependent

• Pseudonormal pattern can mask true dysfunction


2. Tissue Doppler imaging (TDI)

Assesses myocardial relaxation directly. Sample at septal and lateral mitral annulus.




Key variables: • e′ (Ea): early diastolic annular velocity

• a′ (Aa): late diastolic annular velocity

• s′: systolic annular velocity


Interpretation: • Reduced e′ is the earliest marker of diastolic dysfunction

• Septal e′ < 7 cm/s or lateral e′ < 10 cm/s indicates abnormal relaxation


E/e′ ratio: • Surrogate of LV filling pressure

• Average E/e′ > 14 suggests elevated LV filling pressures

• Less reliable in significant MR, MAC, regional wall motion abnormalities


3. Pulmonary venous flow

Obtained with pulsed-wave Doppler in right upper pulmonary vein.




Components: • S wave: systolic forward flow

• D wave: diastolic forward flow

• Ar wave (PA): atrial reversal


Key findings: • Normal: S ≥ D

• Elevated LV filling pressure: D > S

• PA duration > mitral A duration (PA d > MA d) suggests raised LVEDP


Useful to unmask pseudonormal filling.


4. Left atrial size

Reflects chronic diastolic burden rather than acute filling pressures.




• LA volume index > 34 mL/m² indicates chronically elevated LV filling pressures

• Normal LA size does not exclude early diastolic dysfunction


5. Tricuspid regurgitation velocity

Used to estimate pulmonary artery systolic pressure.




• TR velocity > 2.8 m/s supports elevated LV filling pressures (if no primary pulmonary disease)


6. Color M-mode flow propagation velocity (Vp)

Measures speed of early diastolic inflow propagation.




• Vp < 45 cm/s suggests impaired relaxation

• E/Vp ratio > 2.5 correlates with elevated LV filling pressure

Less commonly used now but helpful in tachycardia or atrial fibrillation.


GRADING OF DIASTOLIC DYSFUNCTION (SIMPLIFIED)


Grade I – Impaired relaxation

• E/A < 1

• e′ reduced

• Normal or mildly elevated filling pressures

• Common in aging and early disease


Grade II – Pseudonormal filling

• E/A 1–1.5

• Reduced e′

• Elevated filling pressures

• Requires integration of E/e′, LA size, TR velocity, pulmonary venous flow


Grade III – Restrictive filling

• E/A ≥ 2

• Short DT (<150 ms)

• Markedly elevated filling pressures

• Poor prognosis

• May be reversible or fixed


DIAGNOSTIC ALGORITHM (CLINICALLY USED)


In patients with normal LVEF: Assess four variables:


1. Average E/e′



2. Septal or lateral e′ velocity



3. LA volume index



4. TR velocity




• ≥3 abnormal → diastolic dysfunction present

• 2 abnormal → indeterminate

• ≤1 abnormal → normal diastolic function


SPECIAL CLINICAL SITUATIONS


Atrial fibrillation: • No A wave

• Use average E/e′, TR velocity, LA size, DT

• Beat averaging mandatory


Mitral valve disease: • Mitral inflow unreliable

• Rely more on TDI, pulmonary venous flow, LA size


Hypertrophic cardiomyopathy: • Severe relaxation abnormality with small LV cavity

• Elevated filling pressures despite preserved EF


Restrictive cardiomyopathy / amyloidosis: • Restrictive filling pattern

• Severely reduced e′

• Disproportionately enlarged atria


CLINICAL IMPLICATIONS


• Explains dyspnea in patients with preserved EF

• Guides HFpEF diagnosis

• Predicts outcomes in hypertension, CAD, valvular disease

• Influences volume management and blood pressure control

• Advanced grades carry worse prognosis


KEY PITFALLS


• Single parameter interpretation is unreliable

• Always integrate clinical context and multiple echo indices

• Age significantly affects normal values

• Loading conditions alter Doppler patterns


SUMMARY


Diastolic dysfunction assessment on echocardiography requires an integrated, multiparametric approach. Tissue Doppler velocities, mitral inflow, LA size, TR velocity, and supportive indices together allow accurate grading and estimation of filling pressures. Mastery of these principles is essential for diagnosing HFpEF, evaluating unexplained dyspnea, and improving patient management.


Drmusmanjaved.com



Comments

Popular posts from this blog

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB)

Brugada ECG vs Incomplete Right Bundle Branch Block (iRBBB) Why this differentiation matters Brugada pattern is a malignant channelopathy associated with sudden cardiac death, while incomplete RBBB is usually a benign conduction variant. Mislabeling Brugada as iRBBB can be fatal; overcalling iRBBB as Brugada can lead to unnecessary anxiety and ICD implantation. --- 1. Basic Definitions Brugada ECG Pattern Primary repolarization abnormality Genetic sodium-channel disorder Characteristic ST-segment elevation in V1–V3 Risk of ventricular fibrillation and sudden death Incomplete RBBB (iRBBB) Depolarization abnormality Delay in right ventricular conduction Common in healthy individuals Usually asymptomatic and benign --- 2. ECG Morphology: Side-by-Side Comparison QRS Duration Brugada: QRS usually <120 ms iRBBB: QRS <120 ms, but with RBBB morphology --- V1–V2 Pattern (Key Differentiator) Brugada Pseudo-RBBB appearance ST elevation ≥2 mm ST segment is coved or saddleback Terminal QRS bl...

Acute Treatment of Hyperkalemia

Acute Treatment of Hyperkalemia – A Practical, Bedside-Oriented Guide Hyperkalemia is a potentially life-threatening electrolyte abnormality that demands prompt recognition and decisive management. The danger lies not only in the absolute potassium value but in its effects on cardiac conduction, which can rapidly progress to fatal arrhythmias. Acute treatment focuses on three parallel goals: stabilizing the cardiac membrane, shifting potassium into cells, and removing excess potassium from the body. Understanding this stepwise approach helps clinicians act quickly and rationally in emergency settings. Why Hyperkalemia Is Dangerous Potassium plays a key role in maintaining the resting membrane potential of cardiac myocytes. Elevated serum potassium reduces the transmembrane gradient, leading to slowed conduction, ECG changes, ventricular arrhythmias, and asystole. Importantly, ECG changes do not always correlate with potassium levels, so treatment decisions should be based on clinical c...

π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š

 π˜Όπ™£π™©π™žπ™˜π™€π™–π™œπ™ͺπ™‘π™–π™©π™žπ™€π™£ π˜Όπ™›π™©π™šπ™§ π™Žπ™©π™§π™€π™ π™š in  Patient with AF and acute IS/TIA European Heart Association Guideline recommends: • 1 days after TIA • 3 days after mild stroke • 6 days after moderate stroke • 12 days after severe stroke Early anticoagulation can decrease a risk of recurrent stroke and embolic events but may increase a risk of secondary hemorrhagic transformation of brain infarcts.  The 1-3-6-12-day rule is a known consensus with graded increase in delay of anticoagulation between 1 and 12 days after onset of ischemic stroke or transient ischemic attack(TIA), according to neurological severity based on European expert opinions. However, this rule might be somewhat later than currently used in a real-world practical setting.